AutoCyte arranges finance for PREP customers:
This article was originally published in Clinica
Executive Summary
AutoCyte has secured an agreement with Norwest Financial Leasing, part of the Wells Fargo group, to provide financing for laboratories that wish to acquire the company's PREP automated Pap smear preparation system. Under the deal, customers will be able to avoid capital outlay either by leasing the equipment and purchasing test kits, or by paying a higher per-test price that includes a charge for the equipment. Customers may also purchase the equipment outright. AutoCyte recently received FDA approval for the PREP system after a number of setbacks (See Clinica No 864, p 16), and is currently seeking approval for its SCREEN system, which automates the screening of slides prepared with the PREP system. Last month, AutoCyte and fellow Pap smear company NeoPath agreed a $100 million merger (see Clinica No 862, p 11).
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.